60 Degrees Pharmaceuticals, Inc.
Begin patient enrollment for the pivotal clinical study of tafenoquine for babesiosis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 22 Sep 2024
- Delivered
- by 19 Jul 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initiating patient enrollment in the summer of 2024”
What we found
Evidence strength A What the grades mean
60 Degrees Pharmaceuticals began patient enrollment for the tafenoquine babesiosis study in July 2024, within the stated summer 2024 deadline.
-
A SEC Filing - First Patient Enrolled SEC filing disclosing first patient enrolled at Tufts Medical Center, confirming enrollment initiation in summer 2024
-
B 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study Company announcement confirming patient enrollment had begun by this date
Checked 22 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you 60 Degrees Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-SXTPW-000024 · Corrections policy